The Rise of GLP-1 Drugs: Unveiling New Horizons in the US Healthcare Space

What's Inside

While they were originally developed for the treatment of diabetes, GLP-1 (glucagon-like peptide-1) medications, including Ozempic and Wegovy, have rapidly gained attention for their weight-loss effectiveness.

We explore the implications of GLP-1 drugs on the US healthcare industry, as well as various retail sectors, examining their role in driving retail growth and redefining modern healthcare approaches.

Data in this research report include:

• Proprietary survey data on US consumers reasons for taking GLP-1 medications and their behavior changes
• Total size and year-over-year growth of the US obesity drug market, 2020–2028E
• Recent revenue results of major GLP-1 medications, including Ozempic and Mounjaro
• Year-over-year changes in the share prices of major GLP-1 manufacturers, January 2023–August 2024

Companies mentioned in this report include: Amazon, Amgen, Bayer, Cigna Group, Costco, Kroger, Eli Lilly, NIKE, Novo Nordisk, Pfizer, Walmart

Other relevant research:

• What the Ozempic Economy Means for US Retail
• Decoding the GLP-1 Trend: How Is the Ozempic Economy Impacting CPG Retail?
• Data Dive: The Global Obesity Economy—Shaped by the Spending of 1 Billion Consumers
• Market Navigator: US Healthcare—Evolving To Become More Personalized and Consumer-Focused
• Visit the Coresight Research Food, Grocery and CPG Retail Hub to explore sector data, reports and company profiles.